comparemela.com

Latest Breaking News On - Infus nurs - Page 1 : comparemela.com

BD Seeks to Transform Patient Experience through Vision of One-Stick Hospital Stay

BD Seeks to Transform Patient Experience through Vision of One-Stick Hospital Stay
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Effect of infusion set replacement intervals on catheter-related bloodstream infections (RSVP): a randomised, controlled, equivalence (central venous access device)–non-inferiority (peripheral arterial catheter) trial

Effect of infusion set replacement intervals on catheter-related bloodstream infections (RSVP): a randomised, controlled, equivalence (central venous access device)–non-inferiority (peripheral arterial catheter) trial
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.

First-of-its-Kind Randomized Clinical Trial Published in The Lancet Infectious Diseases Outlines Potential New Standard-Setting Best Practices for Peripheral IV Catheters

Share this article Share this article FRANKLIN LAKES, N.J., Feb. 2, 2021 /PRNewswire/  BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that new clinical data have found robust evidence that using a vascular care solution can help improve outcomes for patients requiring peripheral intravenous catheters (PIVCs). The results of the CLEAN3 trial The Lancet Infectious Diseases, showed the use of the BD vascular care solution resulted in fewer PIVC failures compared with the standard group (34.8% vs. 47.5%, respectively) and extended the median time between catheter insertion and failure (50.4 hours vs 30.0 hours, respectively). PIVC failure was defined as any premature removal of PIVC before end of treatment – other than for routine replacement – and included phlebitis, infiltration, occlusion, dislodgment, local infection and catheter-related bloodstream infection (whichever occurred first).

First-of-its-Kind Randomized Clinical Trial Published in The Lancet Infectious Diseases Outlines Potential New Standard-Setting Best Practices for Peripheral IV Catheters

(2) - There is robust evidence that the BD vascular care solution and skin antiseptic for peripheral intravenous catheters used in the CLEAN3 randomized clinical trial can help improve patient outcomes - Compared with standard approaches, the BD vascular care solution reduced the relative risk of catheter failure by 27%, resulting in longer catheter dwell time without complications - The use of 2% CHG 70% IPA single use, sterile applicator skin antiseptic reduced the risk of infectious complications (catheter colonization and local infection) by 92% compared with 5% povidone iodine (PVI) 69% ethanol FRANKLIN LAKES, N.J., Feb. 2, 2021 /PRNewswire/ BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that new clinical data have found robust evidence that using a vascular care solution can help improve outcomes for patients requiring peripheral intravenous catheters (PIVCs).

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.